NASDAQ:XOMA XOMA (XOMA) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free XOMA Stock Alerts $24.05 +0.71 (+3.04%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$23.25▼$24.3250-Day Range$19.52▼$26.3252-Week Range$13.48▼$26.83Volume19,834 shsAverage Volume20,361 shsMarket Capitalization$279.70 millionP/E RatioN/ADividend YieldN/APrice Target$74.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get XOMA alerts: Email Address XOMA MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside207.7% Upside$74.00 Price TargetShort InterestHealthy2.36% of Shares Sold ShortDividend StrengthN/ASustainability-0.22Upright™ Environmental ScoreNews Sentiment0.97Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.73) to ($1.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.07 out of 5 starsMedical Sector208th out of 938 stocksPharmaceutical Preparations Industry91st out of 433 stocks 3.5 Analyst's Opinion Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.00, XOMA has a forecasted upside of 207.7% from its current price of $24.05.Amount of Analyst CoverageXOMA has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.36% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently decreased by 5.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for XOMA is -0.22. Previous Next 2.8 News and Social Media Coverage News SentimentXOMA has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for XOMA this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.73) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About XOMA Stock (NASDAQ:XOMA)XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More XOMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XOMA Stock News HeadlinesMarch 23, 2024 | americanbankingnews.comXOMA (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving Average of $18.73March 21, 2024 | globenewswire.comXOMA Declares Quarterly Preferred Stock DividendsMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 19, 2024 | globenewswire.comXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.March 13, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEMarch 8, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023March 8, 2024 | finance.yahoo.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueMarch 8, 2024 | globenewswire.comXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 28, 2024 | globenewswire.comXOMA to Present at Upcoming Investor Conferences in MarchFebruary 19, 2024 | businesswire.comKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEFebruary 18, 2024 | msn.comCompare with Maple Leaf Green World Inc (4HV0)February 17, 2024 | finance.yahoo.comXOMA Mar 2024 20.000 putFebruary 17, 2024 | finance.yahoo.comXOMA Jun 2024 25.000 callFebruary 16, 2024 | benzinga.comBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate BiopharmaFebruary 16, 2024 | marketwatch.comXOMA Agrees to Acquire Kinnate BiopharmaFebruary 16, 2024 | finance.yahoo.comXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightFebruary 16, 2024 | finance.yahoo.comXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightFebruary 16, 2024 | globenewswire.comXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightJanuary 20, 2024 | finance.yahoo.comWith 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investorsJanuary 11, 2024 | markets.businessinsider.comXOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPCJanuary 11, 2024 | tmcnet.comFDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxJanuary 11, 2024 | marketwatch.comXoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolJanuary 11, 2024 | markets.businessinsider.comXoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For ArimoclomolJanuary 11, 2024 | finance.yahoo.comFDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxJanuary 8, 2024 | seekingalpha.comXoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairmanJanuary 6, 2024 | wsj.comXOMA Corp. Dep. Pfd. (Rep. 8.375% Cum. Pfd. Series B)See More Headlines Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CUSIP98419J10 CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees13Year Founded1981Price Target and Rating Average Stock Price Target$74.00 High Stock Price Target$74.00 Low Stock Price Target$74.00 Potential Upside/Downside+207.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,830,000.00 Net Margins-886.91% Pretax Margin-858.16% Return on Equity-25.17% Return on Assets-17.08% Debt Debt-to-Equity Ratio1.34 Current Ratio8.68 Quick Ratio8.68 Sales & Book Value Annual Sales$4.76 million Price / Sales58.76 Cash FlowN/A Price / Cash FlowN/A Book Value$7.72 per share Price / Book3.12Miscellaneous Outstanding Shares11,630,000Free Float11,021,000Market Cap$279.70 million OptionableOptionable Beta0.58 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Owen P. Hughes Jr. (Age 49)CEO & Director Comp: $193.75kMr. Thomas M. Burns (Age 50)Senior VP of Finance & CFO Comp: $759.24kMr. Brad Sitko (Age 43)Chief Investment Officer Comp: $867.08kKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLVerastemNASDAQ:VSTMVanda PharmaceuticalsNASDAQ:VNDAMerrimack PharmaceuticalsNASDAQ:MACKProgenics PharmaceuticalsNASDAQ:PGNXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 6,841 shares on 3/11/2024Ownership: 3.668%Vanguard Group Inc.Bought 6,841 shares on 2/15/2024Ownership: 3.669%Opaleye Management Inc.Sold 24,500 shares on 2/15/2024Ownership: 2.176%Barclays PLCBought 8,722 shares on 2/15/2024Ownership: 0.088%Citadel Advisors LLCSold 2,300 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions XOMA Stock Analysis - Frequently Asked Questions Should I buy or sell XOMA stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA shares. View XOMA analyst ratings or view top-rated stocks. What is XOMA's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for XOMA's shares. Their XOMA share price targets range from $74.00 to $74.00. On average, they predict the company's share price to reach $74.00 in the next year. This suggests a possible upside of 207.7% from the stock's current price. View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts. How have XOMA shares performed in 2024? XOMA's stock was trading at $18.50 on January 1st, 2024. Since then, XOMA stock has increased by 30.0% and is now trading at $24.05. View the best growth stocks for 2024 here. When is XOMA's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XOMA earnings forecast. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Friday, March, 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.13. The biotechnology company earned $1.83 million during the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative trailing twelve-month return on equity of 25.17% and a negative net margin of 886.91%. What is John Varian's approval rating as XOMA's CEO? 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO). Who are XOMA's major shareholders? XOMA's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.67%), Vanguard Group Inc. (3.67%), Opaleye Management Inc. (2.18%), Stonepine Capital Management LLC (2.18%), Dimensional Fund Advisors LP (0.22%) and Barclays PLC (0.09%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Owen Hughes and Thomas M Burns. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XOMA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.